Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 357

1.

Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.

Madras BK, Gracz LM, Fahey MA, Elmaleh D, Meltzer PC, Liang AY, Stopa EG, Babich J, Fischman AJ.

Synapse. 1998 Jun;29(2):116-27.

PMID:
9593102
2.

Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain.

Madras BK, Gracz LM, Meltzer PC, Liang AY, Elmaleh DR, Kaufman MJ, Fischman AJ.

Synapse. 1998 Jun;29(2):105-15.

PMID:
9593101
3.

Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain.

Madras BK, Meltzer PC, Liang AY, Elmaleh DR, Babich J, Fischman AJ.

Synapse. 1998 Jun;29(2):93-104.

PMID:
9593100
4.

Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.

Fischman AJ, Bonab AA, Babich JW, Palmer EP, Alpert NM, Elmaleh DR, Callahan RJ, Barrow SA, Graham W, Meltzer PC, Hanson RN, Madras BK.

Synapse. 1998 Jun;29(2):128-41.

PMID:
9593103
5.

Preparation and biological evaluation of iodine-125-IACFT: a selective SPECT agent for imaging dopamine transporter sites.

Elmaleh DR, Fischman AJ, Shoup TM, Byon C, Hanson RN, Liang AY, Meltzer PC, Madras BK.

J Nucl Med. 1996 Jul;37(7):1197-202.

6.

[(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites.

Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC, Madras BK.

Synapse. 2001 Mar 15;39(4):332-42.

PMID:
11169784
8.

Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121.

Staley JK, Boja JW, Carroll FI, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Mash DC.

Synapse. 1995 Dec;21(4):364-72.

PMID:
8869167
9.

Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.

Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.

J Nucl Med. 1998 Jul;39(7):1143-8.

10.

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA.

J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):133-40.

11.

Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.

Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, Charney DS, van Dyck CH, Hoffer PB, Innis RB.

J Nucl Med. 1997 Sep;38(9):1453-9.

12.

Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.

Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J.

Nucl Med Commun. 2001 Jun;22(6):721-5.

PMID:
11403185
13.

The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus.

Niznik HB, Fogel EF, Fassos FF, Seeman P.

J Neurochem. 1991 Jan;56(1):192-8.

PMID:
1987318
14.

Correlative single photon emission computed tomography imaging of [123I]altropane binding in the rat model of Parkinson's.

Gleave JA, Farncombe TH, Saab C, Doering LC.

Nucl Med Biol. 2011 Jul;38(5):741-9. doi: 10.1016/j.nucmedbio.2010.12.006. Epub 2011 Mar 30.

PMID:
21718949
15.

Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.

Kim HJ, Im JH, Yang SO, Moon DH, Ryu JS, Bong JK, Nam KP, Cheon JH, Lee MC, Lee HK.

J Nucl Med. 1997 Nov;38(11):1703-11.

16.

Distribution of cocaine recognition sites in rat brain: in vitro and ex vivo autoradiography with [125I]RTI-55.

Fujita M, Shimada S, Fukuchi K, Tohyama M, Nishimura T.

J Chem Neuroanat. 1994 Jul;7(1-2):13-23.

PMID:
7802967
18.

Characterization of the dopamine transporter in nonhuman primate brain: homogenate binding, whole body imaging, and ex vivo autoradiography using [125I] and [123I]IPCIT.

al-Tikriti MS, Zea-Ponce Y, Baldwin RM, Zoghbi SS, Laruelle M, Seibyl JP, Giddings SS, Scanley BE, Charney DS, Hoffer PB, et al.

Nucl Med Biol. 1995 Jul;22(5):649-58.

PMID:
7581176
19.

SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.

Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T.

J Neurol Sci. 2001 Jun 15;187(1-2):55-9.

PMID:
11440745
20.

Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.

Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB.

J Nucl Med. 1998 Sep;39(9):1500-8.

Supplemental Content

Support Center